Table 1.
Characteristics of included studies.
| Study design | Study site | Study period | Patients | Intervention | Comparator | |
|---|---|---|---|---|---|---|
| Abd-Elsalam et al., 20208 | Randomized controlled trial | Multicenter in Egypt | From June 23, 2020 to August 23, 2020 | Patient with COVID-19 | 50 mg of elemental zinc twice daily and hydroxychloroquine for 15 days | Hydroxychloroquine |
| Abdallah et al., 20226 | randomized, double-blind, placebo-controlled trial | Multicenter in Tunisia | from February 15, 2022 to May 4, 2022 | Adult patients with COVID-19 | 25 mg of elemental zinc twice daily for 15 days | Placebo |
| Patel et al., 20219 | Phase 2a double‐blind, randomized controlled trial | Single center in Australia | From September 3, 2021 to November 9, 2021 | Hospitalized adults with COVID-19 | 0.24 mg/kg/day of elemental zinc for a maximum of 7 days | Placebo |
| Thomas et al., 20217 | randomized clinical open-label trial | Multicenter in US | from April 27, 2020, to October 14, 2020 | Adult patients with COVID-19 | 50 mg of zinc at Bedtime for 10 days |
Standard of care |